



STADA Friday Fact

Look into the future: “Polypill” divides Europe

Bad Vilbel, 31 July 2020 – Taking a “polypill” every day to prevent potential cardiovascular illnesses when older? A clear “maybe”: according to the results of the STADA Health Report 2020, every other European believes this would be a good idea and is open to taking a combination tablet that contains several active ingredients. However, the other half appears to be far from convinced. Indeed, 18 percent of polypill opponents say that they will not take any such medicine so long as they are feeling fine – even if doing so could prevent illnesses in future.

The highest number of sceptics are to be found in Austria and Switzerland: in these countries, just 38 percent can imagine taking a polypill. More appreciation for a ‘pill against age-related illnesses’ can be seen in Poland (64 percent) and Russia (65 percent).

These are the results of the second international STADA Health Report, a representative study of more than 24,000 participants in 12 countries. The market research institute Kantar was commissioned by STADA Arzneimittel AG to interview around 2,000 people aged between 18 and 99 in each of Austria, Belgium, Finland, France, Germany, Italy, Poland, Russia, Serbia, Spain, Switzerland and the UK around the theme of “Do all roads lead to health?”. Further information on the STADA Health Report 2020 and much more can be found at: <https://www.yourhealth.stada/>



About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (Chairman) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez
Chairman of the Supervisory Board: Dr. Günter von Au